Astellas Pharma Day
February 8, 2022 3:30 PM - 5:00 PM
MassBioHub, 700 Technology Square, 5th Floor Cambridge MA 02139
Add to Calendar
2/8/2022 3:30:00 PM
2/8/2022 5:00:00 PM
Astellas Pharma Day
Accelerate your biotech company, startup, or university’s innovation portfolio at our Astellas 2022 Pharma Day on February 8.
MassBio’s Pharma Days® are unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies.
Connect on February 8 | Innovators with small molecule, gene therapy, mRNA, or cell therapy candidates or technology in the therapeutic areas listed below who are actively looking for licensing opportunities are encouraged to apply for a one-on-one virtual meeting with Astellas representatives. Astellas’ target therapeutic areas are:
Applications for one-on-one meetings can be found here, and must be submitted by January 7, 2022 at 12:00AM (midnight) ET.
Protection of intellectual property rights (ex. patents, trademarks, copyright, trade secrets, etc.) of your concept is your responsibility and your responsibility alone. Information you include in your application will be shared with State of Possible partners. Please note that these partners did NOT sign Non-Disclosure Agreements (NDAs). Therefore, you should not include any information in your application that you feel could be harmful to your company should that information be disclosed.
MassBioHub, 700 Technology Square, 5th Floor Cambridge MA 02139
MassBio’s Pharma Days® are unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies.
Connect on February 8 | Innovators with small molecule, gene therapy, mRNA, or cell therapy candidates or technology in the therapeutic areas listed below who are actively looking for licensing opportunities are encouraged to apply for a one-on-one virtual meeting with Astellas representatives. Astellas’ target therapeutic areas are:
• Oncology
• Immuno-Science
• Mitochondria Biology
• Regeneration/Reprogramming
• Immuno-Science
• Mitochondria Biology
• Regeneration/Reprogramming
Applications for one-on-one meetings can be found here, and must be submitted by January 7, 2022 at 12:00AM (midnight) ET.
Protection of intellectual property rights (ex. patents, trademarks, copyright, trade secrets, etc.) of your concept is your responsibility and your responsibility alone. Information you include in your application will be shared with State of Possible partners. Please note that these partners did NOT sign Non-Disclosure Agreements (NDAs). Therefore, you should not include any information in your application that you feel could be harmful to your company should that information be disclosed.
MassBioHub, 700 Technology Square, 5th Floor Cambridge MA 02139
Head of Early Stage Partnering, Astellas
Dr. Michael Luther is the Head of Early Stage Partnering at Astellas based in Cambridge. Mike has over 34 years’ experience as an entrepreneurial scientist and executive in the biopharmaceutical industry including roles in biotech start-ups and global pharmaceutical industry.
Before joining Astellas, Mike was the founding CEO of Bantam Pharmaceutical, a biotech company focused on developing novel therapeutics in cancer and mitochondrial dynamics.
In past roles, Mike was the Senior Vice President for Drug Discovery & Development at Curio and founding CEO of the North Carolina Research Campus.
Mike has over 20 years in executive roles in the global pharmaceutical industry including Vice President roles and head of drug discovery divisions at Merck and GSK. At GSK, he led multiple discovery teams that resulted in the successful launch of 4 new therapeutics in oncology and metabolic disease as well as initiating the pharmaceutical industry’s initial efforts in precision medicine and drug repositioning.
Dr. Luther holds Bachelor of Science degrees from North Carolina State University, a doctorate degree from St. Louis University School of Medicine, and an MBA from Duke University. He was a Carl Stone Muscular Dystrophy Fellow at The Salk Institute, and is the author of over 70 publications and patents.
Brought to you by
Brought to you by